$1.83
▼ -1.6% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
Overview
52-week range
$0.98
$4.46
24% of range
Avg surprise (last 3)
+7.7%
Avg reaction (last 2)
-1.1%
50% positive
Latest IV / EM
114%
EM ±26.1% · $2 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.18 | $-0.19 | +5.3% | +35.7% | +1.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.23 | $-0.28 | +17.9% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.28 | $-0.28 | 0.0% | — | -3.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.32 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.35 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.54 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.16 | -$0.23 | +30.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-46M | — | $-45M | $-57M | $-65M | — | $-72M | $-71M |
| Net income | $-43M | — | $-41M | $-51M | $-60M | — | $-66M | $-66M |
| EPS (diluted) | $-0.18 | — | $-0.19 | $-0.23 | $-0.28 | — | $-0.32 | $-0.35 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $52M | $38M | $52M | $42M | $75M | $51M | $171M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $273M | $258M | $261M | $283M | $292M | $303M | $304M | $457M |
| Total assets | $396M | $416M | $440M | $471M | $508M | $549M | $589M | $647M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $117M | $123M | $124M | $126M | $123M | $127M | $125M | $132M |
| Total equity | $279M | $293M | $315M | $345M | $385M | $422M | $464M | $515M |